According to IssueWire, “Code Pharma plans to launch an Initial Public Offering (IPO) on the NASDAQ and Switzerland’s SIX Swiss Exchange. The company had launched a limited fundraising round for international expert investors, allowing them to acquire its shares at a 20% discount with a minimum of USD 100,000 starting from November 25, 2021. All these have made the valuation of Code Pharma rise to USD 250 million”.
CEO and Founder, Zyon Ayni. said on the press release: “The entire team of Code Pharma is very excited today. We are a company of people playing an important role in the race to develop a cure for COVID-19. Our drug Codivir, was first discovered at the Hebrew University in Israel and it has a very good safety profile and very impressive antiviral activity, both under laboratory conditions and in our Phase I clinical trials”.
